Sharman V L, Abrams S M, Adami S, Cattell W R, Chaput de Saintonge D M, Greenwood R N, Goodwin F J, Hately W, Hattersley L A, Marsh F P, Morgan A G, Muir J W, O'Riordan J L, Papapoulos S E, Revell P, Tucker A K, Baker L R
Proc Eur Dial Transplant Assoc. 1983;19:287-92.
Seventy-six patients receiving regular haemodialysis, without biochemical or radiological evidence of renal osteodystrophy, entered a five-year double-blind placebo-controlled trial of calcitriol (1,25-dihydroxycholecalciferol) in the prevention of bone disease. Significantly more patients on placebo developed bone disease as judged by a sustained elevation of plasma alkaline phosphatase or the development of sub-periosteal erosions on hand radiographs. Serum parathyroid hormone fell significantly in the patients receiving calcitriol and was significantly lower than in patients receiving placebo. It is concluded that calcitriol delays and may prevent the development of metabolic bone disease in patients receiving regular haemodialysis therapy.
76名接受常规血液透析且无肾性骨营养不良生化或放射学证据的患者，进入了一项为期五年的双盲安慰剂对照试验，该试验使用骨化三醇（1,25 - 二羟胆钙化醇）预防骨病。根据血浆碱性磷酸酶持续升高或手部X线片上出现骨膜下侵蚀判断，接受安慰剂的患者中发生骨病的人数明显更多。接受骨化三醇治疗的患者血清甲状旁腺激素显著下降，且明显低于接受安慰剂的患者。得出的结论是，骨化三醇可延缓并可能预防接受常规血液透析治疗患者代谢性骨病的发生。
